The EPS beat and cash runway into Q4 2027 provide near-term stability, but the stock's movement will depend on clinical data readouts in 1H 2027. Monitor for patient enrollment updates and any financing announcements, as the current cash burn rate may necessitate future capital raises.
Price Chart
Executive Summary
Kalaris Therapeutics reported Q1 2026 net loss per share of $(0.46), beating consensus of $(0.52) by 11.5%. The company continues to advance its lead candidate TH103 in a Phase 1b/2 study for neovascular AMD, with preliminary data expected in 1H 2027. Cash and equivalents stood at $104.9M, expected to fund operations into Q4 2027.
Key Financial Metrics
Key Facts
- Net loss per share $(0.46) vs consensus $(0.52) (11.5% beat)
- Net loss of $10.9M in Q1 2026 vs $10.2M in Q1 2025
- Cash, cash equivalents and marketable securities of $104.9M as of March 31, 2026
- Phase 1b/2 trial of TH103 screening patients; preliminary data expected 1H 2027
- R&D expenses increased to $7.6M from $6.0M year-over-year
Financial Impact
EPS beat of $0.06 per share vs consensus; cash burn rate ~$10.9M/quarter
Risk Factors
- Clinical trial failure or delays in TH103 development
- Cash burn may require dilutive financing before data readout
- No approved products or revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292781 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13G | $1.80 | awaiting T+60 | — | $1.79 (−0.56%) |
Aug 11, 2026 11w ago | 8-K | $3.97 | awaiting T+60 | — | $1.79 (−54.91%) |
Aug 11, 2026 11w ago | Press Release | $3.97 | awaiting T+60 | — | $1.79 (−54.91%) |
Aug 3, 2026 12w ago | 3 | $4.32 | awaiting T+60 | — | $1.79 (−58.56%) |
Jul 20, 2026 14w ago | 8-K | $4.00 $2.23 | ▼ −44.25% | ▼ −49.09% | $1.79 (−55.25%) |
Jul 17, 2026 14w ago | 8-K | $4.38 $2.26 | ▼ −48.40% | ▼ −53.09% | $1.79 (−59.13%) |
Jul 17, 2026 14w ago | Press Release | $4.38 $2.26 | ▼ −48.40% | ▼ −53.09% | $1.79 (−59.13%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.36 $3.90 | ▼ −10.55% | ▼ −14.95% | $1.79 (−58.94%) |
May 12, 2026 24w ago | 8-K | $4.79 $4.19 | ▼ −12.53% | ▼ −16.91% | $1.79 (−62.63%) |
May 12, 2026 24w ago | Press Release | $4.79 $4.19 | ▼ −12.53% | ▼ −16.91% | $1.79 (−62.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers